The management of locally advanced prostate cancer.
The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.
Valicenti
R K
RK
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107-5097, USA. richard.valicenti@mail.tju.edu
D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*